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Introduction
Although brain tumors are relatively rare, they represent approximately 2% of all cancer diseases and constitute an important cause of morbidity and mortality.
The age-adjusted SEER 1 (Surveillance Epidemiology and End Results from the National Cancer Institute) incidence of brain tumors is approximately 6.6/100 000 in the United States [1] . Gliomas comprise approximately 33% of all brain tumors and 79% of malignant brain tumors [2] . It is a group of heterogeneous neoplasms that differ in location within the central nervous system, age and sex distribution, growth potential, invasiveness, morphological features, tendency for progression and response to treatments. The most common malignant glioma is the glioblastoma, which is associated with a median survival of 12 −15 months.
Temozolomide is an oral drug that is rapidly metabolized into methyltriazenoimidazole-carboxamide (MTIC 2 ), a DNA-methylating drug. A DNA repair enzyme, methyl-guanine methyltransferase (MGMT 3 ), can remove the methyl group and overcome the modification of cells that lack MGMT, which have been shown to have a higher sensitivity to temozolomide. The EORTC 4 
(European Organization for
Research and Treatment of Cancer) has published a study on the concomitant use of radiation therapy and adjuvant temozolomide, which slightly improved mortality (9.8% after 5 years). This treatment is now adopted as the new standard treatment.
In addition to temozolomide, other compounds (bevacizumab, VEGF receptor tyrosine kinase inhibitors [pazopanib, lapatinib, erlotinib], procarbazine, lomustine and vincristine) have been tested in clinical trials, but only the phase II studies have 1 Arsenic trioxide (As 2 O 3 ) has also been shown to be effective in glioma cells and in mice models. This compound can induce autophagy and apoptosis [3] , and it inhibits at relatively low concentrations in U87 and T98G cells in vitro [4] . This finding was confirmed with orthotopic malignant gliomas growing in the brains of mice but only in combination with radiotherapy [5] .
In this paper, we focus on an organoarsenical drug (i.e., Arsthinol, STB 5 , Fig.1 ), which displays an anticancer activity. This drug was marketed in 1953 as amoebicide tablets [6, 7] , and it has recently demonstrated a strong anticancer activity after intravenous (i.v.) injections [8] [9] [10] [11] [12] [13] .
From a chemical perspective, STB belongs to the dithiarsolane series, which includes melarsoprol (MEL B 6 ) as the lead compound. This latter drug is used as a trypanocide in Africa, and its formulation in propylene glycol can lead to adverse side effects, often causing severe pain for patients during i.v. injection. Because these drugs are very poorly soluble in water, we also suspect their precipitation in plasma as soon as the drug enters the vein and is diluted in the blood, which can lead to thrombosis in some cases.
The i.v. use of the drug has also been limited because of its cerebral toxicity. After injection, the rapid increase in concentration can lead to arsenical encephalopathy.
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A few years ago, we proposed cyclodextrin (CD 7 ) complexes (hydroxypropyl-ßcyclodextrin/melarsoprol and methyl-ß-cyclodextrin/melarsoprol) that could allow for oral absorption [14] . These complexes were characterized by an improved absorption and reduced peak/valley ratio. As expected, the tolerance for this formulation was better, and surprisingly, the therapeutic effect was also significantly improved, with no CNS toxicity observed at therapeutic dose [15] .
We attempted to apply this concept to STB/cyclodextrin complexes. This dithiarsolane was chosen because it has the best anticancer activity of this series of compounds, to our knowledge [11, 13, 16 ].
Materials and methods

Materials
STB and melarsoprol were synthesized according to the method described by Friedheim [9, 17, 18] . Its chemical structure is presented in Fig. 1 . The organoarsenic purity was greater than 99%, confirmed by the HPLC analysis, and its structure was ascertained by 1 H-and 13 C-NMR. 
Phase solubility studies of STB complexation
STB complexation with various cyclodextrins was evaluated using the phasesolubility method [19] . A suspension of a large excess of STB in 2 mL of aqueous solutions of the appropriate CD (concentrations ranging from 9.5 to 191 mM in 0.1 M phosphate buffer pH 7.4) was stirred in screw-capped amber vials for 18 h on a rockand-roller agitator at 25°C. Under these conditions, the solution primarily contained the non-ionized STB (pKa 9.5, [20] ), and no significant degradation of the drug was observed. Preliminary time-dependence experiments showed that the equilibrium was reached after this period of stirring. Each suspension was then centrifuged at 7200 × g for 5 min and diluted 1:100 with 0.1 M phosphate buffer pH 7.4; the amount of dissolved STB was then quantified by HPLC as described above.
The apparent solubility of the substrate ([STB] t ) was determined as a function of the added ligand concentration ([CD] t ). Because the phase solubility diagrams were of AL-type and a 1:1 complex was assumed, the apparent stability (or formation) constant Kc was calculated for each CD using the slope from the linear regression analysis of the phase-solubility isotherm using the following equation:
Eq. (1) The inherent solubility of STB (S0) was determined in pure water under identical conditions. The determinations were performed in triplicate, and the constants were expressed as the mean ± S.D.
Determination of the apparent complexation constant by potentiometric titration
For the potentiometric titration procedure, a set of solutions with increasing concentrations of CD (2.5 × 10 -5 to 6 × 10 -5 M) and a constant drug content (1 × 10 -5 M) were prepared, with a final volume of 16 mL.
To maintain the ionic strength, phosphate buffer (0.1 M, pH 7.4) was used. A control STB solution was also prepared in the phosphate buffer medium without CD to calculate the reference K a value. After one hour of incubation at room temperature to allow for complexation, the solutions were acidified to pH 4 with 0.05 M HCl and then 0.05 M KOH was added progressively up to pH 11 to form the titration curve. After each KOH addition, the pH was recorded. The pH and titrant volumes were used to calculate the K a value through the second derivative method [21] .
The apparent complexation constant was calculated as previously described by Kahle and colleagues [22] .
Determination of the complex structure by 1 H-NMR measurements
Because the results that we obtained were similar for both cyclodextrins, we chose to focus on HPßCD for the remainder of the study. Additionally, this cyclodextrin was already complexed with melarsoprol and this drug has now an "orphan drug designation" from the European Medicine Agency (i.e., trypanocidal activity of the melarsoprol/HPßCD complex [15] ). The results from 1 H NMR, 13 The classical MTT test was used to determine growth inhibition and cytotoxic activity after treatment with STB, STB*HPßCD, As 2 O 3 or melarsoprol. Exponentially growing cells were seeded into 96-well plates (4 x 10 4 cells/mL) and incubated with each compound at different concentrations (0.01 µM to 1 mM, 24 h or 48 h, 37°C, 5% CO 2 ). Cell viability was directly proportional to the production of formazan (λ = 570 nm).
Animal studies
Pathogen-free, 6-8 week-old female athymic NMRI-nu (nu/nu) mice were purchased from Charles River (Saint Germain sur l'Arbresle, France).
Animal handling procedures were performed in accordance with national animal care guidelines (European Commission directive 86/609/CEE; French decree no. 87-848).
Animals were housed in solid-bottomed plastic cages with free access to tap water and food ad libitum. Rearing conditions were a room temperature of 23 ± 1°C, a relative humidity of 60%, and a 12h/12h light/dark cycle.
Maximum Tolerated Dose (MTD)
Maximum Tolerated Doses (MTD) were determined to set the doses of animal experiments. Groups of 5 animals have received various doses of STB*RAMEßCD and As 2 O 3 (i.p. and oral) 5 days/week. The first dose was set from our experience of these compounds [9] (0.15 mmol/kg for STB*RAMEßCD and 0.06 mmol/kg for As 2 O 3 ) and was increased by steps of 0.01 mmol/kg. The highest dose that results in no lethality, <15% weight loss and no other sign of toxicity was recorded as MTD.
Glioma mouse model
U87 MG is a commonly studied grade IV glioma cell line (anaplastic astrocytoma, ATCC HTB-14) that has been studied for more than four decades. These cells were cultured in monolayers as described above.
Heterotopic tumor grafts were achieved as followed: a subcutaneous injection of 10 6 U87 MG cells (in 5% glucose) was performed into each hind leg of mice. Tumors obtained from these source mice were used for the production of heterotopic Treatments started when the volume of the tumor exceeded 280 ± 50 mm 3 , and the solutions [STB*RAMEßCD (i.p. and oral), arsenic trioxide (i.p. and oral)] were administered 5 days/week. Each group (treated and control) was composed of 9 mice.
Since the route of administration were i.p. and oral, the bioavailability is always bellow 100% and this may impact the efficacy of the treatment, we chose to compare each group at 65% of the MTD (see section 3.5).
The size of the tumor was measured with a vernier caliper 3 times a week.
Experiments were stopped when the size reached 2000 mm 3 (survival endpoint).
Other ethical parameters inconsistent with the continued life of animals, such as a weight loss of greater than 15% of initial weight, major disturbances in physiological and/or neurological functions, were also taken into account as endpoints.
The Mann-Whitney U test was used to evaluate the statistical significance of the results. Kaplan-Meier curve analysis was performed for survival analysis, using the log-rank test (GraphPad Prism version 5.00 for Mac Os X, GraphPad Software, San Diego California USA). The amount of total arsenic in the samples was determined using a colorimetric method [23] after digestion with nitric acid (HNO 3 ; 65%) and hydrogen peroxide 12 (H 2 O 2 ; 30%). In brief, each sample (tissues or plasma) was placed in a digestion tube with 5 mL HNO 3 (65%) and 5 mL H 2 O 2 (30%). The tubes were heated with a digester apparatus DK-20 (Velp Scientifica, Milan, Italy) by slowly increasing the temperature from 100°C to 200°C. The clear solution was evaporated to dryness, and the residue was solubilized with 10 mL of HCl (2 M) and introduced into an arsine generator apparatus (European Pharmacopoeia). The reaction was initiated by zinc powder after reduction to trivalent arsenic (As III ) with tin chloride (SnCl 2 ; 40%) and potassium iodide (KI; 15%). After 30 min, the pentavalent arsenic (As V ) was completely reduced to arsine (AsH 3 Our main objective was to develop a complex of STB with cyclodextrins (STB*RAMEßCD and STB*HPßCD). To our knowledge, this STB compound was the best anticancer dithiarsolane [9, 13] ; it is a lipophilic compound (log P = 2.34), and its solubility is very poor, though slightly better than that of melarsoprol.
The classical phase solubility study, first described by T. Higuchi and K.A. Connors [19] , demonstrates the potent solubility properties of cyclodextrins. RAMEßCD and HPßCD showed a very good solubilization effect on STB (Fig. 2 ). Both cyclodextrins isotherms were linear within the CD concentration range studied, corresponding to A L -type profile with a slope less than 1 and indicating that the inclusion complexes could be of the first order with respect to the CDs (1:1 stoichiometry).
In this case, the method can be used for the determination of K c using the slope of the curve. However, the standard deviation was very large (24 058 ± 20 738 M -1 for HPßCD and 18 697 ± 7426 M -1 for RAMEßCD). Therefore, these results should be confirmed by another method. obtained as follows ( Fig. 3) :
Eq. (6) Eq. (7) The first titration curve (i.e., without CD) displays the pK a of STB (9.61 ± 0.12 [ Fig.   3 ]) and was consistent with the value published by Hiskey in 1968 [20] . These values were consistent with those of the dissolution study. We therefore considered this complexation to have a very strong association.
Determination of the complex structure by 1 H-NMR measurements
A 2D-ROESY experiment was used to characterize the inclusion complex of STB and 2-hydroxypropyl-β-cyclodextrin. This technique is widely used and enables the identification of host-guest intermolecular interactions [33] . In our case, the overlapping of the STB peaks (b, c, d, g, Table 1 ) with those of cyclodextrin (between 3.5 and 4 ppm) and the variation of chemical shifts when passing from pure solution to complex and when changing the solvent made the identification of intermolecular cross peaks with the aromatic portion ambiguous (Fig. 4a ).
To avoid this problem and clearly identify the complex, we used the large spectral dispersion of 13 The intensities of the NOESY correlation peaks allowed us to characterize, in relative terms, the interatomic distances. From these intensities (green circles, Fig. 4b ), we can say that the proton (e') is the nearest proton of 5 and 6, followed by the proton (e) and finally the proton (f) (whose correlation can result from relayed interactions, not from direct spatial proximity).
This study suggests that the aromatic ring is deeply inserted into the cavity following the scheme proposed in Fig. 5 .
In vitro activity
The results have confirmed that this organoarsenical drug, such as arsenic trioxide [3] , has a potential for the treatment of glioma.
Because STB was more cytotoxic than A2O3, the toxicity/activity ratio (therapeutic index T.I. = LD 50 /IC 50 ) was used for a better comparison among the three compounds. The LD 50 values were previously published [9] , and the IC 50 values were taken from the 48 h time point (Fig 6) . The T.I. ratio, which was 16.8 for As 2 O 3 and 12.6 for melarsoprol, was significantly improved for STB (T.I. = 143).
Until this study, dithiarsolanes (i.e., melarsoprol or STB) had not been tested for the treatment of glioma, and the only proven use of these compounds for treating cancer had been described for leukemias [24] . During the last decade, the anticancer properties of trivalent arsenical derivatives have been partially elucidated. Their strong activity has been attributed to the linkage between the arsenical compounds and the thiol moieties present on numerous proteins.
As 2 O 3 is the main arsenical compound that has been studied and tested on a series of glioma cells (U373, U87, U251, GBI, A-172 and T98G) [25] . Since STB*HPßCD is administered orally and necessarily dissociated during digestion, the IC 50 of STB is relevant to discuss the efficacy of this compound.
Nevertheless, we have shown that the cytotoxicity of this complex is 31,6 ± 9.7 µM.
In vivo experiments
The MTD are detailed in table 2. These results confirm that STB*RAMEßCD has a lower toxicity than As 2 O 3 and are in good agreement with the results previously obtained for STB LD 50 [9] .
In subsequent experiments, we chose doses of 65% of the MTD for administration of i.p. STB*RAMEßCD, i.p. As 2 O 3 and oral As 2 O 3 . For oral STB*RAMEßCD, the MTD was too high, and for technical reasons, it was not possible to give more than 3 mmol/kg; consequently, this dose was arbitrarily fixed at 10 × the i.p. dose ( Table 2 ).
During the treatment of the tumor-bearing mice, the animals were inspected daily for signs of pain, distress or morbidity.
The For each curve, a progressive growth ( Fig. 7) of the average tumor volume has been observed in the first days until the first animal until the first animal died.
Compared with the control group, the average tumor volume increases more slowly after i.p. administration of As 2 O 3 or STB*HPßCD (Fig. 7a) .
The Kaplan-Maier survival curves are shown in Fig.8a , and the differences between these two groups (i.e., As 2 O 3 i.p. and STB*HPßCD i.p.) are significant (p = 0.049, log-rank [Mantel Cox] test). The median survival after As 2 O 3 i.p. treatment was 15 days a very near that of the control group (14 days), whereas survival after STB*HPßCD i.p. treatment reached 21 days ( Fig. 9 ) and was statistically different from that of the other groups (p<0.05).
The effects observed per os were not statistically different from those of the control group (Fig 7b, 8b) . The median survival of the controls was 13 days. It reached 14 days with As 2 O 3 per os and 17 days with STB*HPßCD per os.
Arsenic amount was analyzed in different organs of few mice treated with STB/HPßCD during 28 days (the maximum duration for per os treatment). It was detected in liver and brain for the i.p. group, and in liver, spleen, kidney, small intestine and brain for the per os group.
For this last group, low concentrations of arsenic were found in the liver and spleen (Table 3) . Higher concentrations were found in the intestine (202 nmol/g), most likely due to the route of administration.
The arsenic concentrations in the heterotopic tumors were 21 nmol/g and 14 nmol/g after i.p. and oral administration, respectively. These values has to be compared with the IC 50 (2.8 ±0.7 µM after 48 h) and the IC 90 (29.9 ± 8.7 µM after 48 h) which are very near these tissue concentrations (Fig. 6 ).
Not surprisingly, the brain, which contains important amounts of membrane lipids, has high concentrations of the drug (693 nmol/g and 217 nmol/g after i.p. and oral administration, respectively). This finding confirms other i.v. studies performed with melarsoprol and STB [34] .
The concentrations of arsenic in the heterotopic tumors were not very high (21 nmol/g and 14 nmol/g after i.p. and oral administration, respectively), although the efficacy was good. This study was performed on heterotopic tumors, which were 20 chosen as a first step for their simplicity. However, an orthotopic tumor would likely be impacted by the high concentrations of drug in the brain tissue.
21
Conclusion
This paper demonstrates that the very poorly soluble drug STB forms a 1:1 inclusion complex with both cyclodextrins (HPßCD and RAMEßCD). Complexed STB (STB*HPßCD) was more effective than arsenic trioxide (As2O3) and melarsoprol on the U87MG cell line. Importantly, the in vivo study did not show any signs of toxicity, and we observed a significant antitumor activity after i.p.
administration.
Consequently, we consider that this treatment is promising, and we believe that the oral route is suitable for this type of drug. The oral complexed melarsoprol that we have studied in previous studies, which is quite similar, gave very good results in a CNS-trypanosomiasis mouse model (i.e., no signs of toxicity and a resolution of CNS-stage infections). 27 Table 3 : Amount of arsenic in organs of mice treated with STB*HPßCD during 28 days..
Mice alive at the end of the study (STB/HPßCD, day 28) are indicated in parentheses.
Amount of arsenic (nmol/g of tissue)
Kidney Intestine Tumor Liver Brain Spleen i.p ND ND 21,3 44 693 ND (n = 2) (n = 1) (n = 2)
Per os 84 ± 61 202 14 12 217 31 (n = 3) (n = 2) (n = 2) (n = 2) (n = 2) (n = 1) 28 29 30 31
